OMS 405

Drug Profile

OMS 405

Alternative Names: OMS 403; OMS405

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Omeros Corporation
  • Developer New York State Psychiatric Institute; Omeros Corporation
  • Class
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Opioid abuse; Smoking withdrawal
  • Preclinical Alcoholism

Most Recent Events

  • 02 Nov 2016 Pharmacodynamics data from a phase II trial in Opioid abuse released by Omeros
  • 19 Oct 2016 Positive pharmacodynamics data from a phase II trial in Opioid abuse released by Omeros
  • 08 Jun 2015 Phase-II development for Opioid abuse and Smoking withdrawal is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top